## IN THE DRITED STATES PATENT AND TRADEMARK OFFICE

ANDREOLETTI, ET AL.

Atty. Ref.:

620-359

Serial No.: Unassigned

Group:

Unassigned

U.S. National Phase of PCT/EP2003/008926

Examiner:

Unassigned

Filed:

February 4, 2005

For:

HETEROPOLYMERIC COMPOUND COMPRISING A

SCAFFOLD, AN ADJUVANT AND AN ANTIGEN, AND ITS

USE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 **February 4, 2005** 

٠,	٠	-	
u	ı		٠

## INFORMATION DISCLOSURE STATEMENT

$\boxtimes$	1.	PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on	the merits] <i>N/C</i>
	2.(a)	Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule Statement or Rule 17(p) fee)]	97(e) N/C
	2 .(b)	Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule Statement or Rule 17(p) fee)]	97(e) <i>\$180.00</i>
	3.	Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97 Statement and Rule 17(p) fee), but before final fee payr	

Best Available Copy

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

$\boxtimes$	4.	A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith. A copy of the International Search Report issued in connection with PCT/EP2003/008926 and references cited are attached.					
This p	paper	is sub	omitted in accordance with:				
$\boxtimes$	5.	37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]					
	6.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and					
		a)	The required Statement made in item 8 below; or				
		b)	The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.				
	7.	37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and					
		a)	The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and				
		b)	The required Statement is stated in item 8 below.				
	8.	Sta	Statement under 37 CFR 1.97(e)				
		a) The undersigned attorney of record hereby certifies under 37 §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from patent office in a counterpart foreign application not more that months prior to the filing of this Information Disclosure Statement item contained in this IDS was the first citation of that item by patent office in a counterpart foreign application which occurrent than three months prior to the filing of this IDS); or					
		b)	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37				

CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

By:

B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000

Facsimile: (703) 816-4100

She	eet 1	of 1			D Re	<b>1 (</b> C'é 'PCT	)/523 /PTO 04	5 9 FEB 2	3005	
INF	ORMA	TION DISCLOSU	RE ATTY.	OCKET NO.	SERIAL	NO.				
	-	CITATION	620-3	859			EP2003/0	08926		
			APPLIC	ANT	Unassigned					
			AND	REOLETTI, ET AL.						
	(Use se	veral sheets if necessary)	FILING		GROUP	<del>,</del>				
			Febru	February 4, 2005		Unassigned				
			U.S	S. PATENT DOCUMENTS						
*EXAN		DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING IF APPRO		
			_						<u> </u>	
			FOR	CION DATENT DOOLINEN	ITC I					
			FUR	EIGN PATENT DOCUMEN	115			TRANS	LATION	
		DOCUMENT	DATE	COUNTRY		CLASS	SUBCLASS	YES	NO	
		WO 00/69907	11/2000	WIPO						
		WO 91/11461	08/1991	WIPO						
		GB 2282813	04/1995	United Kingdom						
		WO 01/00231	01/2001	WIPO					-	
		WO 99/35260	07/1999	WIPO						
						<del></del>				
			-					_		
		OTHER DOCUM	FNTS (in	cluding Author, Title, Date	e Perti	nent na	nes etc	<u> </u>		
j				nd Pharmacotherapy, Dece					 3	
				nunology, January 1, 2000						
		110.010., 1110.000	31 11111		,	.,	<u> </u>			
		ļ								

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

Form PTO-FB-A820 (Also PTO-1449)